Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefixime pharmacokinetics in pregnant and nonpregnant women for congenital syphilis prevention research
ACTRN12625001180404Phase 3Not yet recruiting
- Sponsor
- World Health Organization
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefixime in syphilis and congenital syphilis (CS) (2 arms), sponsored by World Health Organization. Primary endpoint: Pharmacokinetic disposition of single-dose cefixime in healthy pregnant women. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
cefixime
03
Conditions
syphiliscongenital syphilis (CS)
Beyond the preview
Go deeper on ACTRN12625001180404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001180404.